Related Experiment Videos
Conserved gating hinge in ligand- and voltage-dependent K+ channels
Elhanan Magidovich1, Ofer Yifrach
1Department of Life Sciences and Zlotowski Center for Neurosciences, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 84105, Israel.
Biochemistry
|October 20, 2004
Summary
Potassium (K+) channels open and close via a conserved glycine hinge mechanism. Mutations disrupting this hinge prevent channel gating, supporting a universal gating model for ion channels.
Area of Science:
- Molecular Biology
- Biophysics
- Structural Biology
Background:
- Ion channels regulate cellular transport.
- Gating, the process of opening and closing ion channels, is crucial for cellular function.
- Previous studies proposed a glycine hinge mechanism for gating in voltage-independent potassium (K+) channels.
Purpose of the Study:
- To investigate if a similar glycine hinge conformational change underlies pore opening in eukaryotic voltage-dependent potassium (K+) channels.
- To examine the role of the gating hinge in Shaker and BK channels.
Main Methods:
- Site-directed mutagenesis of the gating hinge glycine residues in Shaker and BK channels.
- Assessment of channel pore opening and gating properties following mutations.
Main Results:
- Mutations of the gating hinge glycine in Shaker channels prevented pore opening, which was restored by introducing a secondary glycine.
- A proline mutation at the gating hinge of Shaker channels favored the open state.
- Mutations to alanine in BK channels significantly hindered opening in a graded manner.
- These findings indicate a conserved gating mechanism across different types of K+ channels.
Conclusions:
- The inner helix bending at a conserved glycine gating hinge is essential for the pore opening of both voltage-dependent and independent potassium channels.
- This study supports a universal gating mechanism for potassium channels, involving a conserved glycine hinge.
- The findings have implications for understanding ion channel function and developing targeted therapeutics.